June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
3 citations
,
January 1985 in “PubMed” Hormonal birth control can cause skin issues, but low-dose options and those with antiandrogens may reduce these effects.
33 citations
,
February 1990 in “Journal of the American Academy of Dermatology” Topical cyclosporine led to significant hair growth in some men with male pattern baldness.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
Lipid carriers improve delivery of hair loss treatments to follicles.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
1 citations
,
July 2023 in “Archives of dermatological research” Bimatoprost 0.03% is as effective as minoxidil 2% for eyebrow growth.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
October 2025 in “Indian Dermatology Online Journal” 2.5 mg/ml of triamcinolone acetonide is more effective for treating alopecia areata.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
4 citations
,
September 2019 in “Journal of cosmetic dermatology” Topical bimatoprost 0.01% improves eyebrow density and diameter, especially at the tail.
November 2023 in “Annales de dermatologie et de vénéréologie, FMC” Baricitinib effectively treats severe alopecia for up to 104 weeks.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
May 2011 in “Journal of The American Academy of Dermatology” Objective assessment is needed to accurately determine medication use and adherence.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib was effective in treating both early and late onset alopecia areata.
1 citations
,
January 2001 in “Endocrine Practice” Topical finasteride may help treat facial hirsutism in women.
Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.
33 citations
,
January 2009 in “Contraception” Chlormadinone acetate is a strong, well-tolerated hormone used in birth control and hormone therapy with benefits for menstrual pain and skin conditions.
January 2018 in “International Journal of Medical Reviews and Case Reports” Bimatoprost 0.03% solution may help treat hair loss.
1 citations
,
June 2024 in “British Journal of Dermatology” Mycophenolate mofetil effectively improved skin pigmentation and itching in a woman with lichen planus pigmentosus and frontal fibrosing alopecia.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
1 citations
,
December 1970 in “European journal of endocrinology” Reversed sequential therapy with cyproterone acetate was effective for treating women with hirsutism and related conditions.
April 2023 in “Journal of Investigative Dermatology” Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
Both treatments for localized alopecia areata are equally effective.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”